The Globe and Mail

PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health

TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
Nasdaq

Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease ...

— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...
manilatimes

Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026

Profound also announced that it is launching an initiative to explore the potential of integrating PSMA PET molecular imaging technologies with the TULSA Procedure to support intention-to-treat ...
Nasdaq

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
Barron's

PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve(R) Procedures, Expanding Access to Incision-Free Care for Women's Health

TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...